Preclinical profiling of the immunogenicity of a two-component subunit malaria vaccine candidate based on virosome technology

Human Vaccines

Volumn 4, Issue 2, 2008, Pages 106-114

  Okitsu, Shinji L ^a,d   Mueller, Markus S ^a   Amacker, Mario ^c   Vogel, Denise ^a   Westerfeld, Nicole ^c   Robinson, John A ^b   Zurbriggen, Rinaldo ^c   Pluschke, Gerd ^a  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c Pevion Biotech Ltd   (Switzerland)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Apical membrane antigen 1; Circumsporozoite protein; Malaria; Preclinical profiling; Synthetic peptides; Vaccine; Virosomes

Indexed keywords

AMA 49C1; APICAL MEMBRANE ANTIGEN 1; APICAL MEMBRANE ANTIGEN 49C1; CIRCUMSPOROZOITE PROTEIN; CIRCUMSPOROZOITE PROTEIN UK 39; CROSS REACTING ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; MALARIA VACCINE; PROTOZOON ANTIBODY; UK 39; VIROSOME VACCINE;

ANIMAL EXPERIMENT; ANTIBODY PRODUCING CELL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG SAFETY; EXPERIMENTAL RABBIT; FEMALE; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; LOW DRUG DOSE; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MALARIA; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; RAT; SPECIES DIFFERENCE;

EID: 45849091898     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.4.2.5188     Document Type: Article

References (40)

1. Clyde DF, Most H, McCarthy VC, Vanderberg JP. Immunization of man against sporozite-induced falciparum malaria. Am J Med Sci 1973; 266:169-77.
2. Schofield L, Villaquiran J, Ferreira A, Schellekens H, Nussenzweig R, Nussenzweig V. [gamma] Interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites. Nature 1987; 330:664.
3. Doolan DL, Martinez-Alier N. Immune response to pre-erythrocytic stages of malaria parasites. Curr Mol Med 2006; 6:169-85.
4. Hafalla JC, Rai U, Morrot A, Bernal-Rubio D, Zavala F, Rodriguez A. Priming of CD8+ T cell responses following immunization with heat-killed Plasmodium sporozoites. Eur J Immunol 2006; 36:1179-86.
5. Kappe SH, Buscaglia CA, Nussenzweig V. Plasmodium sporozoite molecular cell biology. Annu Rev Cell Dev Biol 2004; 20:29.
6. Dame JB, Williams JL, McCutchan TF, Weber JL, Wirtz RA, Hockmeyer WT, Maloy WL, Haynes JD, Schneider I, Roberts D. Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. Science 1984; 225:593.
7. Zavala F, Cochrane AH, Nardin EH, Nussenzweig RS, Nussenzweig V. Circumsporozoite proteins of malaria parasites contain a single immunodominant region with two or more identical epitopes. The Journal of Experimental Medicine 1983; 157:1947.
8. Hill AV Pre-erythrocytic malaria vaccines: Towards greater efficacy. Nat Rev Immunol 2006; 6:21-32.
9. Targett GA. Malaria vaccines 1985-2005: A full circle? Trends Parasitol 2005; 21:499-503.
10. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J, Mandomando I, Spiessens B, Guinovart C, Espasa M, Bassat Q, Aide P, Ofori-Anyinam O, Navia MM, Corachan S, Ceuppens M, Dubois MC, Demoitie MA, Dubovsky F, Menendez C, Tornieporth N, Ballou WR, Thompson R, Cohen J. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: Randomised controlled trial. Lancet 2004; 364:1411.
11. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Aide P, Sigauque B, Milman J, Mandomando I, Bassat Q, Guinovart C, Espasa M, Corachan S, Lievens M, Navia MM, Dubois MC, Menendez C, Dubovsky F, Cohen J, Thompson R, Ballou WR. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: Single-blind extended follow-up of a randomised controlled trial. Lancet 2005; 366:2012-8.
12. Narum DL, Thomas AW. Differential localization of full-length and processed forms of PF83/AMA-1 an apical membrane antigen of Plasmodium falciparum merozoites. Molecular and Biochemical Parasitology 1994; 67:59.
13. Peterson MG, Marshall VM, Smythe JA, Crewther PE, Lew A, Silva A, Anders RF, Kemp DJ. Integral membrane protein located in the apical complex of Plasmodium falciparum. Mol Cell Biol 1989; 9:3151-4.
14. Anders RF, Crewther PE, Edwards S, Margetts M, Matthew MLSM, Pollock B, Pye D. Immunisation with recombinant AMA-1 protects mice against infection with Plasmodium chabaudi. Vaccine 1998; 16:240.
15. Collins WE, Pye D, Crewther PE, Vandenberg KL, Galland GG, Sulzer AJ, Kemp DJ, Edwards SJ, Coppel RL, Sullivan JS, et al. Protective immunity induced in squirrel monkeys with recombinant apical membrane antigen-1 of Plasmodium fragile. Am J Trop Med Hyg 1994; 51:711-9.
16. Crewther PE, Matthew ML, Flegg RH, Anders RF. Protective immune responses to apical membrane antigen 1 of Plasmodium chabaudi involve recognition of strain-specific epitopes. Infect Immun 1996; 64:3310-7.
17. Deans JA, Alderson T, Thomas AW, Mitchell GH, Lennox ES, Cohen S. Rat monoclonal antibodies which inhibit the in vitro multiplication of Plasmodium knowlesi. Clin Exp Immunol 1982; 49:297-309.
18. Deans JA, Knight AM, Jean WC, Waters AP, Cohen S, Mitchell GH. Vaccination trials in rhesus monkeys with a minor, invariant, Plasmodium knowlesi 66 kD merozoite antigen. Parasite Immunol 1988; 10:535-52.
19. Kocken CHM, Narum DL, Massougbodji A, Ayivi B, Dubbeld MA, van der Wel A, Conway DJ, Sanni A, Thomas AW. Molecular characterisation of Plasmodium reichenowi apical membrane antigen-1 (AMA-1), comparison with P. falciparum AMA-1, and antibody-mediated inhibition of red cell invasion. Molecular and Biochemical Parasitology 2000; 109:147.
20. Narum DL, Ogun SA, Thomas AW, Holder AA. Immunization with parasite-derived apical membrane antigen 1 or passive immunization with a specific monoclonal antibody protects BALB/c mice against lethal Plasmodium yoelii yoelii YM blood-stage infection. Infect Immun 2000; 68:2899-906.
21. Xu H, Hodder AN, Yan H, Crewther PE, Anders RF, Good ME CD4+ T cells acting independently of antibody contribute to protective immunity to Plasmodium chabaudi infection after apical membrane antigen 1 immunization. J Immunol 2000; 165:389-96.
22. Burns Jr JM, Flaherty PR, Nanavati P, Weidanz WP. Protection against Plasmodium chabaudi malaria induced by immunization with apical membrane antigen 1 and merozoite surface protein 1 in the absence of gamma interferon or interleukin-4. Infect Immun 2004; 72:5605-12.
23. Hodder AN, Crewther PE, Anders RF. Specificity of the protective antibody response to apical membrane antigen 1. Infect Immun 2001; 69:3286-94.
24. Kocken CHM, van der Wel AM, Dubbeld MA, Narum DL, van de Rijke FM, van Gemert GJ, van der Linde X, Bannister LH, Janse C, Waters AP, Thomas AW. Precise timing of expression of a Plasmodium falciparum-derived transgene in Plasmodium berghei Is a critical determinant of subsequent subcellular localization. J Biol Chem 1998; 273:15119-24,
25. Kato K, Mayer DC, Singh S, Reid M, Miller LH. Domain III of Plasmodium falciparum apical membrane antigen 1 binds to the erythrocyte membrane protein Kx. Proc Natl Acad Sci USA 2005; 102:5552.
26. Pfeiffer B, Peduzzi E, Moehle K, Zurbriggen R, Gluck R, Pluschke G, Robinson JA. A Virosome-mimotope approach to synthetic vaccine design and optimization: Synthesis, conformation, and immune recognition of a potential malaria-vaccine candidate. Angew Chem Int Ed Engl 2003; 42:2368.
27. Mueller MS, Renard A, Boato F, Vogel D, Naegeli M, Zurbriggen R, Robinson JA, Pluschke G. Induction of parasite growth-inhibitory antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of Plasmodium falciparum apical membrane antigen 1. Infect Immun 2003; 71:4749.
28. Moreno R, Jiang L, Moehle K, Zurbriggen R, Gluck R, Robinson JA, Pluschke G. Exploiting conformationally constrained peptidomimetics and an efficient human-compatible delivery system in synthetic vaccine design. Chembiochem 2001; 2:838.
29. Bisang C, Jiang L, Freund E, Emery F, Bauch C, Matile H, Pluschke G, Robinson JA. Synthesis, conformational properties, and immunogenicity of a cyclic template-bound peptide mimetic containing an NPNA motif from the circumsporozoite protein of Plasmodium falciparum. J Am Chem Soc 1998; 120:7439-49.
30. Okitsu SL, Kienzl U, Moehle K, Silvie O, Peduzzi E, Mueller MS, Sauerwein RW, Matile H, Zurbriggen R, Mazier D, Robinson JA, Pluschke G. Structure-activity-based design of a synthetic malaria peptide eliciting sporozoite inhibitory antibodies in a virosomal formulation. Chemistry and Biology 2007; 14:577-87.
31. Westerfeld N, Zurbriggen R. Peptides delivered by immunostimulating reconstituted influenza virosomes. J Pept Sci 2005; 11:707.
32. Matile Ha RP, Pernis ILa B. Plasmodium falciparum malaria parasite cultures and their use in immunology: Immunological methods. San Diego, Calif.: Academic Press, 1990:221.
33. Dorn A, Stoffel R, Matile H, Bubendorf A, Ridley RG. Malarial haemozoin/beta-haematin supports haem polymerization in the absence of protein. Nature 1995; 374:269-71.
34. Lambros C, Vanderberg JP. Synchronization of Plasmodium falciparum erythrocytic stages in culture. J Parasitol 1979; 65:418-20.
35. Poltl-Frank F, Zurbriggen R, Helg A, Stuart F, Robinson J, Gluck R, Pluschke G. Use of reconstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide-based vaccine. Clin Exp Immunol 1999; 117:496.
36. James S, Moehle K, Renard A, Mueller MS, Vogel D, Zurbriggen R, Pluschke G, Robinson JA. Synthesis, solution structure and immune recognition of an epidermal growth factor-like domain from Plasmodium falciparum merozoite surface protein-1. Chem Bio Chem 2006; 7:1943-50.
37. Okitsu SL, Boato F, Mueller MS, Li DB, Vogel D, Westerfeld N, Zurbriggen R, Robinson JA, Pluschke G. Antibodies elicited by a virosomally formulated Plasmodium falciparum serine repeat antigen-5 derived peptide detect the processed 47kDa fragment both in sporozoites and merozoites. Peptides 2007; 28:2051-60.
38. Genton B, Pluschke G. A randomized placebo-controlled phase la malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers. PLoS ONE 2007; 2:e1018.
39. Ghasparian A, Moehle K, Linden A, Robinson JA. Crystal structure of an NPNA-repeat motif from the circumsporozoite protein of the malaria parasite Plasmodium falciparum. Chem Commun (Camb) 2006; 174-6.
40. Okitsu SL, Silvie O, Westerfeld N, Curcic M, Kammer AR, Mueller MS, Sauerwein RW, Robinson JA, Genton B, Mazier D, Zurbriggen R, Piuschke G. A virosomal malaria Peptide vaccine elicits a long-lasting sporozoite-inhibitory antibody response in a phase 1a clinical trial. PLoS ONE 2007; 2:e1278.